

# PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Rafia Mehdi Kashmiri	09/03/2007
Jeffrey Schlom	09/12/2007
Eduardo A. Padlan	09/02/2007
RECEIVING PARTY DATA	
Name:	The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
Street Address:	National Institutes of Health
Internal Address:	Office of Technology Transfer, Suite 325, 6011 Executive Boulevard
City:	Rockville
State/Country:	MARYLAND
Postal Code:	20852
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11813092
CORRESPONDENCE DATA	
Fax Number:	(503)595-5301
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	5035955300
Email:	garrett.hinesley@klarquist.com
Correspondent Name:	Anne Carlson, Ph.D.
Address Line 1:	Klarquist Sparkman, LLP
Address Line 2:	121 SW Salmon Street, Suite 1600
Address Line 4:	Portland, OREGON 97204
ATTORNEY DOCKET NUMBER:	4239-69465-06
NAME OF SUBMITTER:	Anne Carlson

CH \$40.00 11813092

**500363544**

**PATENT**  
**REEL: 019889 FRAME: 0013**

**Total Attachments: 9**

source=Assignments\_69465-06#page1.tif  
source=Assignments\_69465-06#page2.tif  
source=Assignments\_69465-06#page3.tif  
source=Assignments\_69465-06#page4.tif  
source=Assignments\_69465-06#page5.tif  
source=Assignments\_69465-06#page6.tif  
source=Assignments\_69465-06#page7.tif  
source=Assignments\_69465-06#page8.tif  
source=Assignments\_69465-06#page9.tif

## ASSIGNMENT

**We, Rafia Mehdi Kashmiri, legal representative of Syed Kashmiri (deceased), of North Potomac, Maryland, Jeffrey Schlom, of Potomac, Maryland, and Eduardo A. Padlan, of Kensington, Maryland, have invented FRAMEWORK RESIDUE SUBSTITUTED HUMANIZED COL-1 ANTIBODIES AND THEIR USE for which the following applications have been filed:**

**U.S. Provisional Application No. 60/640,672, filed December 30, 2004;  
PCT Application No. PCT/US2005/047431, filed December 30, 2005; and  
U.S. Application No. 11/813,092, filed June 28, 2007;  
hereinafter collectively referred to as "the patent applications."**

**We were employed by the Department of Health and Human Services at the time the invention was made. The conditions under which said invention was made are such as to entitle the Government of the United States of America under Paragraph 1(a) of Executive Order 10096, to the entire right, title, and interest in the invention, in the United States and all other countries throughout the world.**

**In consideration of the inventors' obligations under Executive Order 10096, and other valuable consideration, the inventors the undersigned, have sold, assigned, and transferred and do sell, assign, and transfer to The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (hereinafter THE GOVERNMENT), and successors and assigns, the full and exclusive right, title, and interest in the patent applications and invention throughout the United States of America, its territories and dependencies, and all other countries. This includes an assignment of all Letters Patent that may be granted on the invention in the United States of America and all countries throughout the world, and any divisional, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof; and the right to claim priority from the patent applications as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law.**

**We authorize and request the issuance of said Letters Patent to THE GOVERNMENT, as assignee of the entire right, title, and interest to be held as fully and entirely as the same would have been held by us had this assignment not been made.**

**We warrant that there are no outstanding assignments, grants, liens, encumbrances, or agreements either written, oral, or implied that will impair, diminish, limit, or abridge the interest herein conveyed at the time of the execution of the present assignment.**

**We also agree upon reasonable request to communicate to THE GOVERNMENT, its representatives, assigns or agents, any facts known to us respecting the invention, and to testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths, provide all requested documents, and do everything reasonably possible to aid THE GOVERNMENT and its assigns to obtain and enforce proper patent protection for the invention in the United States or any foreign country. These provisions are binding upon the inventors' heirs, legal representatives, administrators and assigns.**

**We have authorized THE GOVERNMENT to file and prosecute these patent applications, as well as any corresponding international or national applications that claim priority from it. THE GOVERNMENT has the right to select attorneys or agents of its choice to prosecute at its discretion these applications on its behalf.**

**We grant the law firm of Klarquist Sparkman, LLP, the power to insert on this Assignment any further information that may be necessary or desirable in order to comply with all applicable legal requirements, including the rules of the United States Patent and Trademark Office, for submitting and recording this document.**

**IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.**

Dated: Sept 3, 2007

Rafia Mehdi Kashmiri  
Rafia Mehdi Kashmiri

Witnessed by Syed M. Fawwaz

Witnessed by Shirley Ann

Name (Print) SYED M. AMIR

Name (Print) SHEILA AMIR

Date Sept. 3 2007

Date SEPT 3, 2007

**Dated:** \_\_\_\_\_

## Jeffrey Schlom

STATE OF \_\_\_\_\_ )  
 )  
COUNTY OF \_\_\_\_\_ ) ss.

This \_\_\_\_ day of \_\_\_\_\_, 2007, before me personally came the above-named Jeffrey Schlom, who executed the foregoing Assignment in my presence, and who acknowledged to me that it was executed under that person's own free will for the purposes set forth therein.

Notary Public for \_\_\_\_\_  
My commission expires: \_\_\_\_\_

[SEAL]

Dated: \_\_\_\_\_

\_\_\_\_\_  
Eduardo A. Padlan

Witnessed by \_\_\_\_\_

Witnessed by \_\_\_\_\_

Name (Print) \_\_\_\_\_

Name (Print) \_\_\_\_\_

Date \_\_\_\_\_

Date \_\_\_\_\_

## ASSIGNMENT

**We, Rafia Mehdi Kashmiri, legal representative of Syed Kashmiri (deceased), of North Potomac, Maryland, Jeffrey Schlom, of Potomac, Maryland, and Eduardo A. Padlan, of Kensington, Maryland, have invented FRAMEWORK RESIDUE SUBSTITUTED HUMANIZED COL-1 ANTIBODIES AND THEIR USE for which the following applications have been filed:**

U.S. Provisional Application No. 60/640,672, filed December 30, 2004;  
PCT Application No. PCT/US2005/047431, filed December 30, 2005; and  
U.S. Application No. 11/813,092, filed June 28, 2007;  
hereinafter collectively referred to as "the patent applications."

We were employed by the Department of Health and Human Services at the time the invention was made. The conditions under which said invention was made are such as to entitle the Government of the United States of America under Paragraph 1(a) of Executive Order 10096, to the entire right, title, and interest in the invention, in the United States and all other countries throughout the world.

In consideration of the inventors' obligations under Executive Order 10096, and other valuable consideration, the inventors the undersigned, have sold, assigned, and transferred and do sell, assign, and transfer to **The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (hereinafter THE GOVERNMENT)**, and successors and assigns, the full and exclusive right, title, and interest in the patent applications and invention throughout the United States of America, its territories and dependencies, and all other countries. This includes an assignment of all Letters Patent that may be granted on the invention in the United States of America and all countries throughout the world, and any divisional, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof; and the right to claim priority from the patent applications as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law.

We authorize and request the issuance of said Letters Patent to THE GOVERNMENT, as assignee of the entire right, title, and interest to be held as fully and entirely as the same would have been held by us had this assignment not been made.

We warrant that there are no outstanding assignments, grants, liens, encumbrances, or agreements either written, oral, or implied that will impair, diminish, limit, or abridge the interest herein conveyed at the time of the execution of the present assignment.

We also agree upon reasonable request to communicate to THE GOVERNMENT, its representatives, assigns or agents, any facts known to us respecting the invention, and to testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths, provide all requested documents, and do everything reasonably possible to aid THE GOVERNMENT and its assigns to obtain and enforce proper patent protection for the invention in the United States or any foreign country. These provisions are binding upon the inventors' heirs, legal representatives, administrators and assigns.

We have authorized THE GOVERNMENT to file and prosecute these patent applications, as well as any corresponding international or national applications that claim priority from it. THE GOVERNMENT has the right to select attorneys or agents of its choice to prosecute at its discretion these applications on its behalf.

We grant the law firm of Klarquist Sparkman, LLP, the power to insert on this Assignment any further information that may be necessary or desirable in order to comply with all applicable legal requirements, including the rules of the United States Patent and Trademark Office, for submitting and recording this document.

IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Dated: \_\_\_\_\_

\_\_\_\_\_  
Rafia Mehdi Kashmiri

Witnessed by \_\_\_\_\_

Witnessed by \_\_\_\_\_

Name (Print) \_\_\_\_\_

Name (Print) \_\_\_\_\_

Date \_\_\_\_\_

Date \_\_\_\_\_

Dated: 9-12-07


Jeffrey Schlom  
Jeffrey Schlom

STATE OF Maryland )  
COUNTY OF Montgomery ) ss.

This 12 day of September, 2007, before me personally came the above-named Jeffrey Schlom, who executed the foregoing Assignment in my presence, and who acknowledged to me that it was executed under that person's own free will for the purposes set forth therein.

Dilia Caridad Herrarte  
Notary Public for Montgomery County, MD.  
My commission expires: Oct 108/2007

[SEAL]



Dated: \_\_\_\_\_

\_\_\_\_\_  
Eduardo A. Padlan

Witnessed by \_\_\_\_\_

Witnessed by \_\_\_\_\_

Name (Print) \_\_\_\_\_

Name (Print) \_\_\_\_\_

Date \_\_\_\_\_

Date \_\_\_\_\_



## ASSIGNMENT

**We, Rafia Mehdi Kashmiri, legal representative of Syed Kashmiri (deceased), of North Potomac, Maryland, Jeffrey Schlom, of Potomac, Maryland, and Eduardo A. Padlan, of Kensington, Maryland, have invented FRAMEWORK RESIDUE SUBSTITUTED HUMANIZED COL-1 ANTIBODIES AND THEIR USE for which the following applications have been filed:**

U.S. Provisional Application No. 60/640,672, filed December 30, 2004;  
PCT Application No. PCT/US2005/047431, filed December 30, 2005; and  
U.S. Application No. 11/813,092, filed June 28, 2007;  
hereinafter collectively referred to as "the patent applications."

We were employed by the Department of Health and Human Services at the time the invention was made. The conditions under which said invention was made are such as to entitle the Government of the United States of America under Paragraph 1(a) of Executive Order 10096, to the entire right, title, and interest in the invention, in the United States and all other countries throughout the world.

In consideration of the inventors' obligations under Executive Order 10096, and other valuable consideration, the inventors the undersigned, have sold, assigned, and transferred and do sell, assign, and transfer to **The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services** (hereinafter **THE GOVERNMENT**), and successors and assigns, the full and exclusive right, title, and interest in the patent applications and invention throughout the United States of America, its territories and dependencies, and all other countries. This includes an assignment of all Letters Patent that may be granted on the invention in the United States of America and all countries throughout the world, and any divisional, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof; and the right to claim priority from the patent applications as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law.

We authorize and request the issuance of said Letters Patent to **THE GOVERNMENT**, as assignee of the entire right, title, and interest to be held as fully and entirely as the same would have been held by us had this assignment not been made.

We warrant that there are no outstanding assignments, grants, liens, encumbrances, or agreements either written, oral, or implied that will impair, diminish, limit, or abridge the interest herein conveyed at the time of the execution of the present assignment.

We also agree upon reasonable request to communicate to **THE GOVERNMENT**, its representatives, assigns or agents, any facts known to us respecting the invention, and to testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths, provide all requested documents, and do everything reasonably possible to aid **THE GOVERNMENT** and its assigns to obtain and enforce proper patent protection for the invention in the United States or any foreign country. These provisions are binding upon the inventors' heirs, legal representatives, administrators and assigns.

We have authorized **THE GOVERNMENT** to file and prosecute these patent applications, as well as any corresponding international or national applications that claim priority from it. **THE GOVERNMENT** has the right to select attorneys or agents of its choice to prosecute at its discretion these applications on its behalf.

We grant the law firm of Klarquist Sparkman, LLP, the power to insert on this Assignment any further information that may be necessary or desirable in order to comply with all applicable legal requirements, including the rules of the United States Patent and Trademark Office, for submitting and recording this document.

**IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.**

**Dated:** \_\_\_\_\_

## Rafia Mehdi Kashmiri

**Witnessed by** \_\_\_\_\_

**Witnessed by** \_\_\_\_\_

**Name (Print)**\_\_\_\_\_

**Name (Print)**\_\_\_\_\_

Date \_\_\_\_\_

Date \_\_\_\_\_

**Dated:** \_\_\_\_\_

## Jeffrey Schlom

STATE OF \_\_\_\_\_ )  
 ) ss.  
COUNTY OF \_\_\_\_\_ )

This \_\_\_\_ day of \_\_\_\_\_, 2007, before me personally came the above-named Jeffrey Schlom, who executed the foregoing Assignment in my presence, and who acknowledged to me that it was executed under that person's own free will for the purposes set forth therein.

Notary Public for \_\_\_\_\_  
My commission expires: \_\_\_\_\_

[SEAL]

Dated: 9/2/07

Eduardo A. Padian  
Eduardo A. Padian

Witnessed by Cristina P. Packard

Name (Print) Cristina P. Packard

Date 9/2/07

Witnessed by Josefina P. Simpson

Name (Print) Josefina P. Simpson

Date 9/2/07